<DOC>
	<DOCNO>NCT00087295</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , FR901228 ( depsipeptide ) , work different way stop tumor cell divide stop grow die . PURPOSE : This phase II trial study well FR901228 work treat patient advanced cancer urothelium progress recur receive one chemotherapy regimen .</brief_summary>
	<brief_title>S0400 , FR901228 Treating Patients With Advanced Cancer Urothelium</brief_title>
	<detailed_description>OBJECTIVES : - Determine response ( confirmed complete partial ) patient advance transitional cell carcinoma urothelium progress prior chemotherapy treat FR901228 ( depsipeptide ) . - Determine progression-free overall survival patient treated drug . - Determine qualitative quantitative toxic effect drug patient . - Determine , preliminarily , effect drug reverse tumor promoter gene methylation patient . - Correlate , preliminarily , tumor DNA plasma response outcome patient treat drug . OUTLINE : This multicenter study . Patients receive FR901228 ( depsipeptide ) IV 4 hour day 1 , 8 , 15 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients achieve complete response receive 2 additional course treatment . Patients follow every 3 month 1 year every 6 month 2 year . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm transitional cell carcinoma urothelium ( bladder , renal pelvis , ureter , urethra ) Metastatic disease Nodepositive , nonmetastatic disease unresectable allow Poorly differentiate transitional cell carcinoma OR predominant transitional cell carcinoma rare foci squamous differentiation rare focus adenocarcinoma allow The following histologic type allow : Adenocarcinoma Small cell carcinoma Sarcoma Squamous cell carcinoma Mixed adeno/squamous/transitional histology Measurable disease At least 1 unidimensionally measurable lesion ≥ 2 cm conventional technique OR ≥ 1 cm spiral CT scan Soft tissue disease irradiate within past 2 month consider measurable Disease progression recurrence 1 , 1 , prior systemic chemotherapy regimen include cisplatin carboplatin metastatic disease Not curable surgery radiotherapy No known brain metastasis PATIENT CHARACTERISTICS : Age Not specify Performance status Zubrod 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 White blood cell ( WBC ) count ≥ 3,000/mm^3 Hepatic Aspartate aminotransferase ( SGOT ) / alanine aminotransferase ( SGPT ) ≤ 2.5 time upper limit normal ( ULN ) Bilirubin normal Renal Creatinine ≤ 2 time ULN Cardiovascular Corrected QT interval ( QTc ) &lt; 500 msec Left ventricular ejection fraction ( LVEF ) &gt; 40 % Multi Gated Acquisition Scan ( MUGA ) No New York Heart Association class III IV congestive heart failure No myocardial infarction within past year No uncontrolled dysrhythmias No poorly control angina No serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No left ventricular hypertrophy EKG No significant cardiac disease Other Potassium ≥ 4 mmol/L Magnesium ≥ 2 mg/dL Not pregnant nursing Fertile patient must use effective contraception No prior allergic reaction compound similar chemical biological composition FR901228 ( depsipeptide ) No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer complete remission PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics At least 28 day since prior chemotherapy No prior FR901228 ( depsipeptide ) No concurrent chemotherapy Endocrine therapy No concurrent hormonal therapy Radiotherapy See Disease Characteristics More 28 day since prior radiotherapy No concurrent radiotherapy Surgery More 28 day since prior surgery Other Recovered prior therapy More 28 day since prior intravesical therapy No concurrent hydrochlorothiazide No concurrent agent cause QTc prolongation No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational histone deacetylase inhibitor agent drug ( e.g. , sodium valproate ) No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
	<keyword>anterior urethral cancer</keyword>
	<keyword>posterior urethral cancer</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
</DOC>